68507-19-7

Basic information

• Product Name: 3-Iodo-4-methoxybenzoic acid
• Synonyms: AKOS BBB/204;3-IODO-4-METHOXYBENZOIC ACID;3-Lodo-4-Methoxybenzoic acid
• CAS NO: 68507-19-7
• Molecular Formula: C₈H₇IO₃
• Molecular Weight: 278.04
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Benzoic acid;API intermediates;Acids & Esters;Anisoles, Alkyloxy Compounds & Phenylacetates;Iodine Compounds
• Mol File: 68507-19-7.mol
• Article Data: 16

Chemical Properties

• Melting Point: 245-248°C
• Boiling Point: 359.9 °C at 760 mmHg
• Flash Point: 171.5 °C
• Appearance: /
• Density: 1.878 g/cm³
• Vapor Pressure: 8.3E-06mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: Room temperature.
• PKA: 4.12±0.10(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 3-Iodo-4-methoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Iodo-4-methoxybenzoic acid(68507-19-7)
• EPA Substance Registry System: 3-Iodo-4-methoxybenzoic acid(68507-19-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-37
• WGK Germany: nwg
• HazardClass: IRRITANT
• Hazardous Substances Data: 68507-19-7(Hazardous Substances Data)

Usage

General Description

3-Iodo-4-methoxybenzoic acid is a chemical compound with the molecular formula C8H7IO4. It is an aromatic carboxylic acid derivative that contains both a methoxy group and an iodo group attached to a benzene ring. 3-Iodo-4-methoxybenzoic acid is commonly used as a building block in organic synthesis and is often utilized in the production of pharmaceuticals and agrochemicals. It has demonstrated potential antibacterial and antifungal properties, making it a valuable compound in the development of new drugs. Additionally, 3-Iodo-4-methoxybenzoic acid is also used in the field of material science as a precursor for the synthesis of various organic and inorganic materials.

InChI:InChI=1/C8H7IO3/c1-12-7-3-2-5(8(10)11)4-6(7)9/h2-4H,1H3,(H,10,11)

Upstream product

• 7553-56-2 iodine 
• 7782-68-5 iodic acid 
• 100-09-4 4-methoxybenzoic acid 
• 15126-06-4 methyl 3-iodo-4-hydroxybenzoate 
• 35387-93-0 3-iodo-4-methoxy-benzoic acid methyl ester 
• 10034-85-2 hydrogen iodide 
• 861524-32-5 2-chloro-1-(3-iodo-4-methoxy-phenyl)-ethanone 
• 79324-77-9 1‐(3‐iodo‐4‐methoxyphenyl)ethan‐1‐one 
• 123-11-5 4-methoxy-benzaldehyde 
• 315675-55-9 3-iodo-4-methoxy-benzoic acid anilide 
• 50597-88-1 2-iodo-4-methylanisole 

Downstream Products

• 89893-95-8 3-iodo-4-methoxybenzoyl chloride 
• 1372125-73-9 (2-ethylbenzofuran-3-yl)(3-iodo-4-methoxyphenyl)methanone 
• 93324-59-5 (2-ethylbenzofuran-3-yl)(4-hydroxy-3-iodophenyl)methanone 
• 315671-35-3 3-iodo-4-methoxy-N-(4-(pyrrolidin-1-ylsulfonyl)phenyl)benzamide 
• 1253290-94-6 2-(4-methoxy-3-[(3-methoxyphenyl)ethynyl]benzoyl)isoindoline 

Relevant articles and documents

Compound for treatment or prevention of hyperuricemia or gout

The invention discloses a compound for treatment or prevention of hyperuricemia or gout. The compound is the compound shown as formula (I) or formula (II) or pharmaceutical acceptable salts thereof. The compound or its pharmaceutical acceptable salts can be applied to urate excretion promotion so as to treat or prevent hyperuricemia or gout. (formula (1), formula (II)).

Regioselective bromination and iodination of aromatic substrates promoted by trans-3,5-dihydroperoxy-3,5-dimethyl-1,2-dioxolane

Selective and efficient bromination and iodination of aromatic compounds by ammonium bromide and ammonium iodide, respectively, under promotion of trans-3,5-dihydroperoxy-3,5-dimethyl-1,2-dioxolane have been explored. Mild reaction conditions, high selectivity and yield, and high reaction rate are some of the major advantages of this synthetic method.

NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE

Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.